PrEP Biopharm Limited announces addition of Jim Cornelius and Clive Page to its Board of Directors

LONDON, Aug. 11, 2016 /PRNewswire/ -- PrEP Biopharm Limited, a private independent drug development company for respiratory infectious disease products, announced that Jim Cornelius, former chairman and CEO of Bristol-Myers Squibb, and Clive Page, PhD, Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology at King's College London, have joined the company's Board of Directors.  They bring expansive strategic, operational and scientific experience to the Board. 

Mr. Cornelius brings a 40-year track record of successful management in the life sciences. He is currently the Chairman of Mead-Johnson Nutrition and in addition to his role at Bristol-Myers Squibb, he previously served as the Chairman and CEO of Guidant Corp, CFO of Eli Lilly and Co and as a director at a dozen public and private companies, including The Chubb Corporation and The DIRECTV Group.

Dr. Page is a world renown expert in the pharmacology of inflammation and respiratory disease who has published more than 250 scientific articles and serves on the board of directors or scientific advisory board of eleven innovative biotechnology companies.

"I'm thrilled to welcome Jim and Clive to PrEP Biopharm's Board," said Ryan Muldoon, CEO of PrEP Biopharm. "As an investor in our series A round, Jim has been with us since our inception, previously serving as an advisor to the Board. His wealth of experience at life science companies both large and small will help PrEP Biopharm both strategically and operationally. Clive's decades of experience in drug development and deep understanding of the biology of inflammation and respiratory disease will be a tremendous asset to PrEP as we continue our Phase 2 work on PrEP-001 for the prevention of upper respiratory viral infections."

"I'm excited to join PrEP Biopharm's Board of Directors and look forward to contributing my insights and helping to build the company," said Mr. Cornelius. "I'm impressed by the data from PrEP-001 so far and the potential that this drug holds for addressing a variety of respiratory viruses, the majority of which have no approved treatments or vaccines."

"I've spent my career looking for ways to address respiratory disease," said Dr. Page. "PrEP Biopharm has come up with a novel approach and have an exciting technology in PrEP-001. I hope to help them shape their approach and development to address an increasingly important unmet need in respiratory viral diseases."

About PrEP Biopharm Limited:

Prep Biopharm Limited is an independent, development stage biopharmaceutical company focused on the prevention of respiratory infections. The privately held company's flagship product, PrEP-001, is in phase 2 for the prevention of upper respiratory tract viral infections.